Sequana/Boehringer Ingelheim asthma research collaboration could be worth $70.5 mil.
Executive Summary
SEQUANA/BOEHRINGER INGELHEIM ASTHMA COLLABORATION COULD BE WORTH $70.5 MIL. to La Jolla, Calif.-based Sequana Therapeutics, the company announced June 14. The research collaboration aims to "identify the genetic causes of asthma" using Sequana's positional cloning techniques.